- Page 1: For further information about lymph
- Page 7 and 8: 3Report of the Technical Advisory G
- Page 9 and 10: P R O G R A M M E H I G H L I G H T
- Page 11: I N T R O D U C T I O N7This Annual
- Page 14 and 15: 10Annual Report on Lymphatic Filari
- Page 16 and 17: 12Annual Report on Lymphatic Filari
- Page 18 and 19: 14Annual Report on Lymphatic Filari
- Page 20 and 21: 16Annual Report on Lymphatic Filari
- Page 22 and 23: 18Annual Report on Lymphatic Filari
- Page 24 and 25: 20Annual Report on Lymphatic Filari
- Page 26 and 27: 22Annual Report on Lymphatic Filari
- Page 28 and 29: 24Annual Report on Lymphatic Filari
- Page 30 and 31: 26Annual Report on Lymphatic Filari
- Page 32 and 33: 28Annual Report on Lymphatic Filari
- Page 34 and 35: 30Annual Report on Lymphatic Filari
- Page 36 and 37: 32Annual Report on Lymphatic Filari
- Page 38 and 39: 34Annual Report on Lymphatic Filari
- Page 40 and 41: 36Annual Report on Lymphatic Filari
- Page 42 and 43: 38Figure 3.2 Outcomes and planning
- Page 44 and 45: 40Annual Report on Lymphatic Filari
- Page 46 and 47: 42Figure 3.14 Outcomes and planning
- Page 48 and 49: 44Figure 3.20 Outcomes and planning
- Page 50 and 51: 46Figure 3.26 Outcomes and planning
- Page 52 and 53:
48Figure 3.32 Outcomes and planning
- Page 54 and 55:
50Figure 3.38 Outcomes and planning
- Page 56 and 57:
52Annual Report on Lymphatic Filari
- Page 59 and 60:
UNITED REPUBLIC OF TANZANIA55Endemi
- Page 61 and 62:
ZANZIBAR, UNITED REPUBLIC OF TANZAN
- Page 63:
59AMERICAN PROGRAMME REVIEWGROUPAt
- Page 66 and 67:
62Figure 3.63 Outcomes and planning
- Page 68 and 69:
64Annual Report on Lymphatic Filari
- Page 70 and 71:
66Annual Report on Lymphatic Filari
- Page 72 and 73:
68Annual Report on Lymphatic Filari
- Page 74 and 75:
70Annual Report on Lymphatic Filari
- Page 76 and 77:
72Figure 3.81 Outcomes and planning
- Page 78 and 79:
74Figure 3.87 Outcomes and planning
- Page 80 and 81:
76Annual Report on Lymphatic Filari
- Page 82 and 83:
78Annual Report on Lymphatic Filari
- Page 84 and 85:
80Figure 3.94 Outcomes and planning
- Page 86 and 87:
82Figure 3.100 Outcomes and plannin
- Page 88 and 89:
84Annual Report on Lymphatic Filari
- Page 90 and 91:
86Annual Report on Lymphatic Filari
- Page 92 and 93:
88Figure 3.118 Outcomes and plannin
- Page 94 and 95:
90Figure 3.124 Outcomes and plannin
- Page 96 and 97:
92Annual Report on Lymphatic Filari
- Page 98 and 99:
94Annual Report on Lymphatic Filari
- Page 100 and 101:
96Annual Report on Lymphatic Filari
- Page 102 and 103:
98Annual Report on Lymphatic Filari
- Page 104 and 105:
100Annual Report on Lymphatic Filar
- Page 106 and 107:
102Annual Report on Lymphatic Filar
- Page 108 and 109:
104Annual Report on Lymphatic Filar
- Page 110 and 111:
106Annual Report on Lymphatic Filar
- Page 112 and 113:
108Annual Report on Lymphatic Filar
- Page 114 and 115:
110Annual Report on Lymphatic Filar
- Page 116 and 117:
112Annual Report on Lymphatic Filar
- Page 118 and 119:
114Figure 3.196 Outcomes and planni
- Page 120 and 121:
116Annual Report on Lymphatic Filar
- Page 122 and 123:
118Annual Report on Lymphatic Filar
- Page 124 and 125:
120Annual Report on Lymphatic Filar
- Page 127:
C H A P T E R 6FURTHER DOCUMENTATIO
- Page 130 and 131:
126Annual Report on Lymphatic Filar
- Page 132 and 133:
128Annual Report on Lymphatic Filar
- Page 135 and 136:
ANNUAL REPORT FOR THE NATIONAL PROG
- Page 137 and 138:
1332. PROGRAMME RESOURCES2.1 Please
- Page 139 and 140:
1353.3 Interruption of transmission
- Page 141 and 142:
1373.3.6a Report of MDA coverage by
- Page 143 and 144:
1393.3.7 Surveys in sentinel sites
- Page 145 and 146:
1413.3.10 Please attach a map of th
- Page 147 and 148:
1434. SERIOUS ADVERSE EXPERIENCES (
- Page 149 and 150:
A N N E X E SANNEX 3: LIST OF LF-EN
- Page 151 and 152:
147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
- Page 153 and 154:
149Drug administration and monitori